Igor Vivanco

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 24, 2025

AKT as a Therapeutic Target in Cancer.

AKT as a Therapeutic Target in Cancer.

Journal: Current topics in microbiology and immunology

Published: November 18, 2025

Dysregulated SASS6 expression promotes increased ciliogenesis and cell invasion phenotypes.

Dysregulated SASS6 expression promotes increased ciliogenesis and cell invasion phenotypes.

Journal: Life science alliance

Published: May 13, 2024

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine.

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine.

Journal: Pharmacogenomics and personalized medicine

Published: September 17, 2021

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.

Journal: Life science alliance

Published: September 16, 2021

Targeting un-MET needs in advanced non-small cell lung cancer.

Targeting un-MET needs in advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 26, 2021

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.

Journal: Gut

Published: July 28, 2020

Inhibitors in AKTion: ATP-competitive vs allosteric.

Inhibitors in AKTion: ATP-competitive vs allosteric.

Journal: Biochemical Society transactions

Published: March 01, 2020

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.

Journal: The Journal of clinical investigation

Published: October 08, 2019

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.

Journal: British journal of cancer

Published: September 10, 2019

EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.

EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.

Journal: Nature communications

Published: March 27, 2017

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.

Journal: PLoS computational biology

Published: January 22, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026